Subventions et des contributions :

Titre :
Polymer conjugation to the Feldan Shuttle to reduce blood protein adsorption and interaction with cell membranes
Numéro de l’entente :
EGP
Valeur d'entente :
25 000,00 $
Date d'entente :
7 mars 2018 -
Organisation :
Conseil de recherches en sciences naturelles et en génie du Canada
Location :
Québec, Autre, CA
Numéro de référence :
GC-2017-Q4-00648
Type d'entente :
subvention
Type de rapport :
Subventions et des contributions
Informations supplémentaires :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).

Nom légal du bénéficiaire :
Gauthier, Marc (Institut national de la recherche scientifique)
Programme :
Subventions d'engagement partenarial pour les universités
But du programme :

For a medication to be effective, it must be able to reach its target. One of the greatest challenges for manyx000D
drugs is that their targets lie inside cells. Indeed, cells are surrounded by a membrane that keeps manyx000D
molecules out - including drugs. Even the most powerful drug will be ineffective if it cannot reach its target.x000D
Feldan Therapeutics Inc. has developed a technology, termed the Feldan shuttle, which facilitates the transferx000D
of several types of drugs into cells. They now face a technological challenge, associated with the stability of thex000D
Shuttle in blood, that they cannot resolve themselves. As such, Feldan Therapeutics Inc. has approached Profx000D
Marc A Gauthier of the INRS to investigate structural alterations to the Shuttle and the influence of thesex000D
modifications on: 1) the physical nature of complexes formed with therapeutic cargo, and 2) their interactionx000D
with blood proteins.